Donovan Polack, MD
Nephrology · Florissant, MONPI 1659324465
Payments from drug & device makers
Across 605 payments — averaging $1293.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$345K
- Akebia Therapeutics Inc$190K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$95K
- Bayer$79K
- Vertex$63K
- Ardelyx, Inc.$6K
- plus $4K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 66 | $344,517 |
| Akebia Therapeutics Inc | 327 | $190,125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $94,838 |
| Bayer | 17 | $79,093 |
| Vertex | 8 | $63,444 |
| Ardelyx, Inc. | 20 | $5,986 |
| Otsuka America Pharmaceutical, Inc. | 25 | $588 |
| Fresenius USA Marketing, Inc. | 16 | $518 |
| Amgen | 21 | $481 |
| AstraZeneca(2 entities) | 24 | $468 |
| Vifor Pharma, Inc. | 21 | $368 |
| Mallinckrodt Enterprises LLC | 5 | $281 |
| Calliditas Therapeutics US Inc. | 7 | $268 |
| Travere Therapeutics, Inc. | 9 | $265 |
| Nxstage Medical, Inc. | 2 | $247 |
| OPKO Pharmaceuticals, LLC | 8 | $225 |
| Boehringer Ingelheim | 7 | $156 |
| Astrazeneca UK Limited | 1 | $135 |
| Novartis | 3 | $86 |
| Lilly USA, LLC | 3 | $79 |
| Mallinckrodt Hospital Products Inc. | 3 | $70 |
| Cormedix Inc. | 1 | $36 |
| Merck | 2 | $29 |
| Cumberland Pharmaceuticals, Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$782,362 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Florissant
- Alejandro AlvarezFlorissant$176K
- Ahmed AwadKansas City$12.4M
- Benjamin HumphreysSaint Louis$1.2M
- Derek LarsonCreve Coeur$605K
- Gary SingerSaint Peters$580K
- Daniel CoyneSaint Louis$563K
- Tarek AlhamadSaint Louis$477K
- Tingting LiSaint Louis$370K
- Anuja JavaSaint Louis$365K
- Marcos RothsteinSaint Louis$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.